Public Market Listing
Live quotes, historical charts, and market capitalization for Oryzon Genomics, S.A. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | LSD1 / KDM1ASmall molecule | Acute Myeloid Leukemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (2)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $0 | — | — | $1.7M | report ↗ |
Oryzon Genomics reported revenue of $0M for H1 2025, with a net loss of €1.59 million, up 52.8% YoY, and a quarterly net burn of $1.74M. R&D spend and cash position were not disclosed.
The company said it expects to generate profits in Q3 2025 and noted that the H1 result does not include a recent €13.2 million CDTI aid package. It also reported receiving €52 million in financing between late 2024 and July 2025, including €30 million from a capital increase, while continuing various drug research programs.
View 1 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q1 | $0 | $2.5M | — | $1.8M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $14M | $33M | — | report ↗ |